

Datasheet: AAI40P

BATCH NUMBER 150106

Description:	GOAT ANTI PIG IgA:HRP
Specificity:	IgA
Format:	HRP
Product Type:	Polyclonal Antibody
Isotype:	Polyclonal IgG
Quantity:	1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Immunohistology - Frozen			▪	
Immunohistology - Paraffin			▪	
ELISA	▪			1/10,000 - 1/100,000
Western Blotting			▪	

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.

Target Species

Pig

Product Form

Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid

Antiserum Preparation

Antisera to porcine IgA were raised by repeated immunisation of goat with highly purified antigen. Purified IgG prepared by affinity chromatography.

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.05% Proclin™ 300
0.2% Bovine Serum Albumin

Approx. Protein Concentrations

IgG concentration 1.0 mg/ml

Immunogen

Purified porcine IgA.

Specificity

Goat anti pig IgA antibody recognizes porcine IgA and shows no cross-reactivity with other porcine immunoglobulin classes as assessed by immunoelectrophoresis. This antibody may cross-react with IgA from other species.

Goat anti Porcine IgA antibody has been successfully used for the evaluation of porcine IgA levels in body fluids of pigs by both ELISA and Western blotting.

References

1. Takahashi, M. *et al* (2005) Correlation between positivity for immunoglobulin A antibodies and viraemia of swine hepatitis E virus observed among farm pigs in Japan. [J Gen Virol. 86: 1807-13.](#)
2. Linghua, Z. *et al*. (2008) *In vivo* oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets. [Vaccine. 26 \(2\): 224-33.](#)
3. Olvera, A. *et al*. (2010) Virulence-associated trimeric autotransporters of *Haemophilus parasuis* are antigenic proteins expressed *in vivo*. [Vet Res. 41: 26.](#)
4. Scharek, L. *et al*. (2005) Influence of a probiotic *Enterococcus faecium* strain on development of the immune system of sows and piglets. [Vet Immunol Immunopathol. 105: 151-61.](#)
5. Scharek, L. *et al*. (2007) Impact of the probiotic bacteria *Enterococcus faecium* NCIMB 10415 (SF68) and *Bacillus cereus* var. *toyoi* NCIMB 40112 on the development of serum IgG and faecal IgA of sows and their piglets. [Arch Anim Nutr. 61: 223-34.](#)
6. Eblé, P.L. *et al*. (2007) Serological and mucosal immune responses after vaccination and infection with FMDV in pigs. [Vaccine. 25: 1043-54.](#)
7. Bestagno, M. *et al*. (2007) Recombinant dimeric small immunoproteins neutralize transmissible gastroenteritis virus infectivity efficiently *in vitro* and confer passive immunity *in vivo*. [J Gen Virol. 88: 187-95.](#)
8. Nakai, I. *et al*. (2006) Different fecal shedding patterns of two common strains of hepatitis E virus at three Japanese swine farms. [Am J Trop Med Hyg. 75: 1171-7.](#)
9. Kang, M.L. *et al*. (2008) Chitosan microspheres containing *Bordetella bronchiseptica* antigens as novel vaccine against atrophic rhinitis in pigs. [J Microbiol Biotechnol. 18: 1179-85.](#)
10. Picherot, M. *et al*. (2007) Swine infection with *Trichinella spiralis*: Comparative analysis of the mucosal intestinal and systemic immune responses. [Vet Parasitol. 143: 122-30.](#)
11. Sheoran A *et al*. (2012) Infection with *Cryptosporidium hominis* provides incomplete protection of the host against *Cryptosporidium parvum*. [J Infect Dis. 205 \(6\): 1019-23.](#)
12. Bestagno, M. *et al*. (2007) Recombinant dimeric small immunoproteins neutralize transmissible gastroenteritis virus infectivity efficiently *in vitro* and confer passive immunity *in vivo*. [J Gen Virol. 88: 187-95.](#)
13. Cordes, H. *et al*. (2012) Cell-mediated and humoral immune responses in pigs following primary and challenge-exposure to *Lawsonia intracellularis*. [Vet Res. 43:9.](#)
14. Crisci, E. *et al*. (2014) Immune characterization of long pentraxin 3 in pigs infected with influenza virus. [Vet Microbiol. 168 \(1\): 185-92.](#)
15. Le Bourgot, C. *et al*. (2016) Short-chain fructooligosaccharide supplementation during gestation and lactation or after weaning differentially impacts pig growth and IgA response

- to influenza vaccination [Journal of Functional Foods. 24: 307-15.](#)
16. Lorenzen, E. *et al.* (2017) Intrauterine inoculation of minipigs with *Chlamydia trachomatis*. during diestrus establishes a longer lasting infection compared to vaginal inoculation during estrus. [Microbes Infect. 19 \(6\): 334-42.](#)
17. Williams, A.R. *et al.* (2017) Dietary cinnamaldehyde enhances acquisition of specific antibodies following helminth infection in pigs. [Vet Immunol Immunopathol. 189: 43-52.](#)
18. Williams, A.R. *et al.* (2017) A polyphenol-enriched diet and *Ascaris suum*. infection modulate mucosal immune responses and gut microbiota composition in pigs. [PLoS One. 12 \(10\): e0186546.](#)
19. López-Serrano, S. *et al.* (2021) Sow Vaccination with a Protein Fragment against Virulent *Glaesserella (Haemophilus) parasuis*. Modulates Immunity Traits in Their Offspring. [Vaccines. 9 \(5\): 534.](#)
20. Tan, T.K. *et al.* (2021) A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. [Nat Commun. 12 \(1\): 542.](#)

Storage	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Proclin™ 300 is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.
Health And Safety Information	Material Safety Datasheet documentation #20391 available at: https://www.bio-rad-antibodies.com/SDS/AAI40P 20391
Regulatory	For research purposes only

Related Products

Recommended Useful Reagents

[AbGUARD® HRP STABILIZER PLUS \(BUF052A\)](#)

[AbGUARD® HRP STABILIZER PLUS \(BUF052B\)](#)

[AbGUARD® HRP STABILIZER PLUS \(BUF052C\)](#)

[TMB CORE \(BUF056A\)](#)

[TMB CORE+ \(BUF062A\)](#)

[TMB SIGNAL+ \(BUF054A\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)
'M363653:200528'

Printed on 01 Mar 2024

